- Trial Phase
- Phase 1b completed; Phase 2 protocol finalized but on hold
- Time to Market
- Unknown. The Phase 2 for the lead indication (allo-HSCT) is paused; a partnered or funded Phase 2 would take 2-3 years to read out, followed by a potential Phase 3. Commercialization is likely 5+ years away absent an accelerated pathway.
- Why 4/10
- SER-155 just passed its nearest catalyst (positive irEC IST data on July 8, 2026), but the pivotal Phase 2 study in allo-HSCT — the Breakthrough Therapy-designated lead indication — is paused pending funding. There is no scheduled PDUFA or pivotal readout within the next ~12 months. Without a hard binary catalyst on the horizon, the score defaults to moderate at 4.
Watch for partnership announcements or licensing deals, especially with large pharma companies holding ICI franchises who could fund SER-155 development in irEC or allo-HSCT. The company's cash runway extends only into Q1 2027, so a capital raise or partnership is a near-term necessity. The stock sold off ~36% on the July 8 positive data day (from $11.60 close to $7.40), suggesting expectations had run ahead of the news.
Price Chart
Executive Summary
SER-155 is Seres Therapeutics' lead live biotherapeutic candidate — an oral bacterial consortia designed to prevent deadly bloodstream infections in stem cell transplant patients. Phase 1b data showed a striking 77% relative risk reduction in bloodstream infections, earning FDA Breakthrough Therapy Designation. The company finalized a Phase 2 protocol with the FDA but paused the study in February 2026 to conserve cash after laying off 30% of staff. A fresh catalyst came July 8, 2026, with positive early data in a second indication (irEC, a nasty side effect of cancer immunotherapy), where 80% of patients responded without immunosuppressives. The stock sold off sharply on the news. SER-155 is clinically compelling but Seres is a cash-constrained micro-cap trading at ~$79M market cap with runway only into Q1 2027, making the stock a binary bet on the company's ability to secure a partnership or funding.
How It Works
SER-155 is an oral "good bacteria" pill — a precisely formulated mix of bacterial strains cultivated in a lab. In patients whose immune systems are knocked down (like stem cell transplant recipients), the gut microbiome becomes vulnerable to pathogen overgrowth that can lead to deadly bloodstream infections. SER-155 works by engrafting beneficial bacteria in the gut that crowd out pathogens, strengthen the gut barrier, and calm inflammation, thereby reducing the risk of infections spreading into the bloodstream.
Trial Status
Phase 1b placebo-controlled Cohort 2 completed (Sep 2024) showing a 77% relative risk reduction in bloodstream infections vs placebo in allo-HSCT patients. FDA granted Breakthrough Therapy Designation (Dec 2024). Phase 2 protocol finalized with FDA feedback (Sep 2025) targeting 248 patients with an interim analysis planned within 12 months of initiation. However, Seres paused further investment in the Phase 2 in Feb 2026 due to capital constraints. An investigator-sponsored open-label trial (n=15) in immune checkpoint inhibitor-related enterocolitis (irEC) reported positive top-line results on July 8, 2026, with 80% (12/15) meeting the primary endpoint.
The Two-Sided Case
Upcoming Catalysts
- Partnership or licensing deal for SER-155 (company actively engaging potential partners for irEC and allo-HSCT development)
- Potential capital raise (equity offering) given cash runway only into Q1 2027
- $12.5M milestone payment from Nestlé Health Science due July 2026 (already teed up)
- Further irEC data updates from the ongoing IST at Memorial Sloan Kettering
- Any decision to resume the paused Phase 2 in allo-HSCT if partnered funding secured
Source Filing
The SecBot filing or press-release report that triggered this drug report:
Seres Therapeutics, Inc. 8-K MCRB ·Originating report